Bringing a therapeutic to market involves considerable risks and requires significant resources. Patents and SPCs covering therapeutics are therefore among the most important and valuable assets that biotech companies own. The core of our Biotechnology team’s work is to protect our clients’ interests in this area.
Our clients in this area range from small companies seeking investment or planning their first clinical trials, to large multinationals with multiple blockbuster products. We recognise the different needs of our diverse range of clients, and pride ourselves on providing bespoke, strategic advice of the highest standard. We understand the importance of the different types of IP incentives to our clients’ commercial operations and we work together with our clients to build an IP strategy that takes into account the interplay between legal and commercial factors specific to human and veterinary therapeutics.
We have an enviable depth of experience tackling some of the particularly difficult issues specific to this area, including the complexities of first, second, and further medical use claims and SPC case law. We are constantly building on our proven track record in fields such as vaccines, antibodies and antisense, and are centrally involved in new growth areas, such as immuno-oncology, cell therapy and the microbiome. We continue to be entrusted with the protection and defence of some of the most important innovations in this area, often for blockbuster and first-in-class products. In recent years we have assisted our clients with therapeutics such as: ABRAXANE®, AVONEX®, BEXSERO®, DARZALEX®, DUPIXENT®, FLUCELVAX®, FORSTEO®, HUMIRA®, IDELVION®, LONQUEX®, PRALUENT®, RESPREEZA®, SIMPONI®, SPINRAZA®, STELARA®, TAKHZYRO®, TREMFYA®, WAYLIVRA® and numerous others.